SGAM
Smith Group Asset Management Portfolio holdings
AUM
$1.53B
1-Year Return
38.67%
This Quarter Return
+12.25%
1 Year Return
+38.67%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.91B
AUM Growth
+$100M
(+5.5%)
Cap. Flow
-$49.7M
Cap. Flow
% of AUM
-2.59%
Top 10 Holdings %
Top 10 Hldgs %
40.66%
Holding
350
New
52
Increased
58
Reduced
147
Closed
44
Top Buys
| 1 |
Lowe's Companies
LOW
|
$23.7M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$22.7M |
| 3 |
SGI
Somnigroup International Inc.
SGI
|
$21M |
| 4 |
Allstate
ALL
|
$20.4M |
| 5 |
Generac Holdings
GNRC
|
$19.1M |
Top Sells
| 1 |
Oracle
ORCL
|
$30.3M |
| 2 |
Ciena
CIEN
|
$25.4M |
| 3 |
Edwards Lifesciences
EW
|
$22M |
| 4 |
Baxter International
BAX
|
$20.9M |
| 5 |
Huntington Ingalls Industries
HII
|
$19.6M |
Sector Composition
| 1 | Technology | 36.47% |
| 2 | Consumer Discretionary | 15.93% |
| 3 | Healthcare | 15.71% |
| 4 | Communication Services | 8.84% |
| 5 | Financials | 8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
TG Therapeutics
TGTX
$5.11B
| $94K | ﹤0.01% |
+3,520
| New | +$94K |
|
|
CCXI
202
DELISTED
ChemoCentryx, Inc.
CCXI
| $90K | ﹤0.01% |
+1,650
| New | +$90K |
|
203
Louisiana-Pacific
LPX
$6.9B
| $79K | ﹤0.01% |
+2,690
| New | +$79K |
|
|
ALLK
204
DELISTED
Allakos
ALLK
| $78K | ﹤0.01% |
960
+310
| +48% | +$25.2K |
|
205
Apellis Pharmaceuticals
APLS
$3.55B
| $78K | ﹤0.01% |
+2,590
| New | +$78K |
|
206
Allogene Therapeutics
ALLO
$255M
| $74K | ﹤0.01% |
+1,970
| New | +$74K |
|
207
Xencor
XNCR
$610M
| $68K | ﹤0.01% |
1,760
| – | – |
|
208
Innospec
IOSP
$2.13B
| $65K | ﹤0.01% |
1,030
-9,308
| -90% | -$587K |
|
209
The RMR Group
RMR
$284M
| $65K | ﹤0.01% |
2,380
-6,620
| -74% | -$181K |
|
210
CareDx
CDNA
$736M
| $63K | ﹤0.01% |
1,650
| – | – |
|
211
Inovio Pharmaceuticals
INO
$148M
| $62K | ﹤0.01% |
+448
| New | +$62K |
|
212
Ironwood Pharmaceuticals
IRWD
$188M
| $61K | ﹤0.01% |
6,830
+2,690
| +65% | +$24K |
|
213
Heron Therapeutics
HRTX
$201M
| $55K | ﹤0.01% |
3,720
+910
| +32% | +$13.5K |
|
214
Bank of America
BAC
$369B
| $50K | ﹤0.01% |
2,095
+50
| +2% | +$1.19K |
|
215
Wells Fargo
WFC
$253B
| $43K | ﹤0.01% |
1,811
+250
| +16% | +$5.94K |
|
|
ICPT
216
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $43K | ﹤0.01% |
1,030
| – | – |
|
217
Blackrock
BLK
$170B
| $42K | ﹤0.01% |
74
+3
| +4% | +$1.7K |
|
218
BHP
BHP
$138B
| $41K | ﹤0.01% |
886
+348
| +65% | +$16.1K |
|
219
Citigroup
C
$176B
| $40K | ﹤0.01% |
930
+90
| +11% | +$3.87K |
|
220
US Bancorp
USB
$75.9B
| $38K | ﹤0.01% |
1,057
+70
| +7% | +$2.52K |
|
221
PNC Financial Services
PNC
$80.5B
| $34K | ﹤0.01% |
309
-13
| -4% | -$1.43K |
|
222
TotalEnergies
TTE
$133B
| $34K | ﹤0.01% |
986
-320
| -25% | -$11K |
|
223
Linde
LIN
$220B
| $31K | ﹤0.01% |
129
-40
| -24% | -$9.61K |
|
224
Regenxbio
RGNX
$490M
| $31K | ﹤0.01% |
1,140
| – | – |
|
225
Bank of New York Mellon
BK
$73.1B
| $30K | ﹤0.01% |
862
+205
| +31% | +$7.14K |
|